Disclosure / CME
Disclosure Information
In accordance with the ACCME Essentials and Standards, anyone involved in planning or presenting this enduring material is required to disclose any relevant financial relationships with commercial interests in the healthcare industry. This information is listed below.
The Medical University of South Carolina, as an ACCME provider, requires that all faculty presenters identify and disclose any off-label uses for pharmaceutical and medical device products. The Medical University of South Carolina recommends that each physician fully review all the available data on new products or procedures prior to instituting them with patients.
Planners and authors with no relevant financial relationships:
David Lo, MB ChB MRCPCH
Planners and authors with relevant financial relationships:
Patrick A. Flume, MD – Research Grants: Bayer Healthcare AG, Boehringer Ingelheim Pharmaceuticals, Gilead Sciences, Inc., Inspire Pharmaceuticals, Inc., Mpex Pharmaceuticals, Inc., Novartis, Pharmaxis Limited, Vertex Pharmaceuticals, Inc., Cystic Fibrosis Foundation, National Institutes of Health; Consultant: Gilead Sciences, Inc., Inspire Pharmaceuticals, Inc.; Speakers Bureau: AstraZeneca.
Manfred Ballmann, MD – Consultant: Nordmark Werke; Advisory Committee/Board: Bayer Healthcare AG, Gilead Sciences, Inc., Insmed Inc., Novartis, Vertex Pharmaceuticals, Inc.
David Geller, MD – Research Grants: Aires Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Gilead Sciences, Inc., Insmed Inc., MicroDose Therapeutx, Mpex Pharmaceuticals, Inc., Novartis, Philips Respironics, Vertex Pharmaceuticals, Inc.; Speakers Bureau: Gilead Sciences, Inc.; Advisory Committee/Board: Gilead Sciences, Inc., Mpex Pharmaceuticals, Inc., Novartis.
Susan Madge, SRN, RSCN, MSc, MCGI, PhD – Advisory Committee/Board: Gilead Sciences, Inc.
Alan Smyth, MA MBBS MCRP MD FRCPCH – Advisory Committee/Board: Mpex Pharmaceuticals, Inc.; Other honoraria: Forest Pharmaceuticals, Inc.
Donald R. VanDevanter, PhD – Consultant: Baxter International Inc., Genentech, Gilead Sciences, Inc., KaloBios Pharmaceuticals, Inc., Mpex Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc.
Credit Designation
The Medical University of South Carolina designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Accreditation Information
The Medical University of South Carolina is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Learning Outcome Objectives
At the completion of this CME enduring material, you should be able to:
- Distinguish between existing/newly available versus investigational aerosolized antibiotics for treating chronic CF respiratory infections
- Apply therapeutic strategies involving intermittent and continuous antibiotic therapy to suppress chronic airway infections using aerosolized antibiotics
- Recognize the importance of clinical outcomes in selecting aerosolized antibiotics for treating pulmonary infections in patients with CF
Successful Completion
To access your CME certificate, you must complete the post-test with a score of 70% or higher and complete the evaluation.
To take the post-test for this article you will need to visit http://tinyurl.com/7nh9utt. Complete the registration form to begin the testing process.
Date of release: 21 December 2011
Expiration date: 20 December 2012